Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07304089 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
A Phase 2 study of Dystonia, sponsored by Vima Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07304089: Recruiting Phase 2 study of Dystonia, sponsored by Vima Therapeutics.
NCT07304089 is a Phase 2 study of Dystonia that is actively recruiting participants, run by Vima Therapeutics. The registered enrollment target is 100 participants, below the 537-participant average among 28 other Dystonia trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07304089, a Phase 2 study of Dystonia, is actively recruiting participants, sponsored by Vima Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Primary Outcome
0-150, higher score worse
Conditions Studied
Interventions
- DRUG VIM0423
- DRUG VIM0423 Placebo
Study Locations (20)
Arizona
- Vima Site #039 - Scottsdale
- Vima Site #004 - Scottsdale
- Vima Site #028 - Sun City
Florida
- Vima Site #009 - Gainesville
- Vima Site #008 - Miami
- Vima Site #031 - Orlando
California
- Vima Site #042 - Irvine
- Vima Site #030 - Los Angeles
Maryland
- Vima Site #043 - Baltimore
- Vima Site #007 - Olney
Michigan
- Vima Site #037 - East Lansing
- Vima Site #002 - Farmington Hills
Alabama
- Vima Site #033 - Birmingham
Colorado
- Vima Site #019 - Denver
Georgia
- Vima Site #005 - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02-05 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What NCT07304089 shows while recruiting
NCT07304089 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 537-participant average among 28 other Dystonia trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Dystonia appearing as the primary indexed condition, and to 2 interventions - of which VIM0423 is the first listed.
NCT07304089 names 20 study sites across 13 states, led by Arizona, Florida, California.
Frequently Asked Questions
What is clinical trial NCT07304089 about?
NCT07304089 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia". Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms c...
What is the current status of trial NCT07304089?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-02-05. Estimated completion is 2027-05.
What conditions does trial NCT07304089 study?
This clinical trial studies the following conditions: Dystonia.
What interventions are being tested in trial NCT07304089?
The interventions under investigation include: VIM0423 (DRUG), VIM0423 Placebo (DRUG).
Who is sponsoring clinical trial NCT07304089?
This trial is sponsored by Vima Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07304089 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dystonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07304089's enrollment target sits among peer trials
100 13th of 28 higher than 15 of 28 other Dystonia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dystonia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand
COMPLETED · Phase 2
-
Effects of Exercise on Dystonia Pathophysiology
RECRUITING · NA
-
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
RECRUITING
-
Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia
RECRUITING · NA
-
Dystonia Genotype-Phenotype Correlation
RECRUITING
-
Sleep-specific DBS Therapy in Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI